Pharmacy Brokerage Services / Confidential Index / PBS-0726
Live sell-side mandate · Project Beacon
A neighborhood pharmacy with an institutional engine.
A confidential opportunity to acquire an independent combination pharmacy in Greater Los Angeles's San Fernando Valley — a retail, long-term-care, and Medicare Part B DME operation dispensing roughly 114,000 prescriptions a year, where a third of the claims drive nearly half of prescription revenue. Identity and full financials are released to qualified buyers under a mutual non-disclosure agreement.
The opportunity
Three businesses under one roof.
Project Beacon is an owner-led independent pharmacy in the San Fernando Valley that runs three complementary lines at once: a retail counter, a long-term-care (LTC) service book, and a Medicare Part B durable-medical-equipment operation. Together they turn roughly 114,000 prescriptions a year — about 9,400 a month.
The LTC book is the engine. It accounts for about a third of claims but nearly half of prescription revenue, because institutional fills reimburse at a meaningful premium to retail. The result is a neighborhood pharmacy that earns like an institutional one — offered on a confidential, success-fee basis, with full detail released under NDA.
The LTC engine
A third of the claims. Nearly half the revenue.
LTC fills reimburse ≈ 1.6× retail — the reason a third of the claims becomes nearly half of the revenue.
Adjusted earnings
A real, add-back-adjusted bottom line.
| Seller P&L — FY2025 | Amount |
|---|---|
| Reported EBITDA | $408,853 |
| Owner add-backs | + $535,013 |
| Adjusted EBITDA | $943,866 |
| Margin on $8.59M revenue | ≈ 11% |
FY2025 adjusted EBITDA of ~$944K on $8.59M of revenue — roughly an 11% margin, built on a documented owner add-back schedule. Prior-year figures and full monthly detail are provided in the CIM.
What's driving it
Value a retail-only buyer would miss.
The earnings rest on payer mix and service breadth — not on foot traffic alone.
The LTC premium
Long-term-care fills reimburse about 1.6× a retail script — $103 versus $65 on average.
Revenue concentration
LTC is ~34% of claims but ~45% of prescription revenue — the profit center inside the pharmacy.
Part B DME line
A Medicare Part B durable-medical-equipment operation diversifies revenue beyond dispensing.
Real volume
~114,000 prescriptions a year — roughly 9,400 a month — across the combined book.
Combination model
Retail, LTC, and DME under one license — a platform a strategic buyer can scale.
Adjusted earnings
~$944K adjusted EBITDA in FY2025 on a documented owner add-back schedule.
At a glance
The blind-teaser snapshot.
Released under NDA
Entity name and licensure, exact location, monthly and dispense-level financials, payer and facility contracts, LTC facility relationships, and the full confidential information memorandum are shared only with qualified buyers under a mutual non-disclosure agreement.
Project Beacon · PBS-0726
Request the confidential memorandum.
Qualified buyers receive the full CIM — identity, financials, and diligence materials — under a mutual NDA. Start with a confidential conversation.
Request the CIM under NDA